Omeros reported a 2018 second quarter net loss of $33.7 million, or $0.70 per share, compared with a net loss of $14.4 million, or $0.33 per share, in 2017’s second quarter.
Revenues for the quarter totaled $1.7 million, all related to the sales of Omidria (phenylephrine 1% and ketorolac 0.3% injection), compared with Omidria revenues of $17.2 million in 2017’s second quarter. With transitional pass-through reimbursement for Omidria unavailable so far in 2018, there has been a significant reduction in its use by ASCs and hospitals, resulting in the revenue (Read more...)
Uncategorized